192 related articles for article (PubMed ID: 34373039)
21. Measuring treatment adverse event burden in myasthenia gravis: Single-center prospective evaluation utilizing the Adverse Event Unit (AEU).
Hehir MK; Conaway M; St Sauveur AB; Feb K; Kolb NA; Waheed W; McNeish BL; Tweedy N; Burns TM
Muscle Nerve; 2024 Jan; 69(1):32-39. PubMed ID: 37676119
[TBL] [Abstract][Full Text] [Related]
22. The Myasthenia Gravis-specific Activities of Daily Living scale as a useful outcome measure and in routine clinical management in Polish patients.
Rozmilowska IM; Adamczyk-Sowa MH; Czyzewski D
Neurol Neurochir Pol; 2018; 52(3):368-373. PubMed ID: 29370887
[TBL] [Abstract][Full Text] [Related]
23. The MG Composite: A valid and reliable outcome measure for myasthenia gravis.
Burns TM; Conaway M; Sanders DB;
Neurology; 2010 May; 74(18):1434-40. PubMed ID: 20439845
[TBL] [Abstract][Full Text] [Related]
24. No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: A systematic retrospective study involving 67 patients.
Wang L; Wang S; Yang H; Han J; Zhao X; Han S; Zhang Y; Lv J; Zhang J; Li M; Ji Y; Zhou S; He X; Fang H; Yang J; Zhang Y; Zhang Q; Gao P; Gao F
Brain Behav; 2021 Jul; 11(7):e02203. PubMed ID: 34075720
[TBL] [Abstract][Full Text] [Related]
25. MG-ADL: still a relevant outcome measure.
Muppidi S; Wolfe GI; Conaway M; Burns TM;
Muscle Nerve; 2011 Nov; 44(5):727-31. PubMed ID: 22006686
[TBL] [Abstract][Full Text] [Related]
26. Promising efficacy of Low-Dose rituximab in Muscle specific kinase antibody positive Myasthenia Gravis.
Yang X; Zhang W; Chang X; Li Z; Du R; Guo J
Neurosci Lett; 2024 Jan; 818():137561. PubMed ID: 37984485
[TBL] [Abstract][Full Text] [Related]
27. A new and easily used modified myasthenia gravis score.
Sathirapanya P; Wiputhanuphongs K; Liabsuetrakul T; Khanittanuphong P; Keeratichananont W
Neuromuscul Disord; 2020 Aug; 30(8):656-660. PubMed ID: 32771266
[TBL] [Abstract][Full Text] [Related]
28. Sensitivity of MG-ADL for generalized weakness in myasthenia gravis.
de Meel RHP; Raadsheer WF; van Zwet EW; Verschuuren JJGM; Tannemaat MR
Eur J Neurol; 2019 Jun; 26(6):947-950. PubMed ID: 30417962
[TBL] [Abstract][Full Text] [Related]
29. Translation and validation of the arabic version of the revised 15-item myasthenia gravis quality-of-life questionnaire.
Alanazy MH; Abuzinadah AR; Muayqil T
Muscle Nerve; 2018 Apr; 57(4):581-585. PubMed ID: 28857210
[TBL] [Abstract][Full Text] [Related]
30. Measuring Overall Severity of Myasthenia Gravis (MG): Evidence for the Added Value of the MG Symptoms PRO.
Regnault A; Morel T; de la Loge C; Mazerolle F; Kaminski HJ; Habib AA
Neurol Ther; 2023 Oct; 12(5):1573-1590. PubMed ID: 37166675
[TBL] [Abstract][Full Text] [Related]
31. Myasthenia gravis activities of daily living profile.
Wolfe GI; Herbelin L; Nations SP; Foster B; Bryan WW; Barohn RJ
Neurology; 1999 Apr; 52(7):1487-9. PubMed ID: 10227640
[TBL] [Abstract][Full Text] [Related]
32. Validation of the Italian version of the Myasthenia Gravis Impairment Index (MGII).
Pasqualin F; Barnett C; Guidoni SV; Albertini E; Ermani M; Bonifati DM
Neurol Sci; 2022 Mar; 43(3):2059-2064. PubMed ID: 34505205
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial.
Bril V; Benatar M; Andersen H; Vissing J; Brock M; Greve B; Kiessling P; Woltering F; Griffin L; Van den Bergh P;
Neurology; 2021 Feb; 96(6):e853-e865. PubMed ID: 33219142
[TBL] [Abstract][Full Text] [Related]
34. A population-based follow-up study of maximal muscle strength and mobility in patients with myasthenia gravis.
Thomsen JLS; Vinge L; Harbo T; Andersen H
Neuromuscul Disord; 2022 Apr; 32(4):305-312. PubMed ID: 35279342
[TBL] [Abstract][Full Text] [Related]
35. Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity.
Bedlack RS; Simel DL; Bosworth H; Samsa G; Tucker-Lipscomb B; Sanders DB
Neurology; 2005 Jun; 64(11):1968-70. PubMed ID: 15955957
[TBL] [Abstract][Full Text] [Related]
36. International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r.
Burns TM; Sadjadi R; Utsugisawa K; Gwathmey KG; Joshi A; Jones S; Bril V; Barnett C; Guptill JT; Sanders DB; Hobson-Webb L; Juel VC; Massey J; Gable KL; Silvestri NJ; Wolfe G; Cutter G; Nagane Y; Murai H; Masuda M; Farrugia ME; Carmichael C; Birnbaum S; Hogrel JY; Nafissi S; Fatehi F; Ou C; Liu W; Conaway M
Muscle Nerve; 2016 Dec; 54(6):1015-1022. PubMed ID: 27220659
[TBL] [Abstract][Full Text] [Related]
37. Long-term efficacy and safety of leflunomide combined with low-dose prednisone in treatment of myasthenia gravis: a retrospective study.
Qiu L; Chen P; Ou C; Deng J; Huang Z; Lin Z; Ma Q; Huang X; Yu L; Ran H; Liu W
Acta Neurol Belg; 2024 Feb; 124(1):175-182. PubMed ID: 37656361
[TBL] [Abstract][Full Text] [Related]
38. Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors.
Fionda L; Rossini E; Lauletta A; Leonardi L; Tufano L; Costanzo R; Marchetti P; Salvetti M; Garibaldi M; Morino S; Antonini G
Neurol Sci; 2024 Mar; 45(3):1243-1247. PubMed ID: 38108913
[TBL] [Abstract][Full Text] [Related]
39. Correlation between myasthenia gravis-activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) assessments of anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis in the phase 3 regain study.
Vissing J; O'Brien F; Wang JJ; Howard JF
Muscle Nerve; 2018 Aug; 58(2):E21-E22. PubMed ID: 29684239
[No Abstract] [Full Text] [Related]
40. Leflunomide treatment in corticosteroid-dependent myasthenia gravis: an open-label pilot study.
Chen P; Feng H; Deng J; Luo Y; Qiu L; Ou C; Liu W
J Neurol; 2016 Jan; 263(1):83-8. PubMed ID: 26514837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
